Gabriel Herrero-Beaumont

List of Publications by Year
in descending order

179 papers	11,978 citations	47006 47 h-index	28297 105 g-index
184 all docs	184 docs citations	184 times ranked	10454 citing authors

#	Article	IF	Citations
1	Blocking chondrocyte hypertrophy in conditional Evc knockout mice does not modify cartilage damage in osteoarthritis. FASEB Journal, 2022, 36, e22258.	0.5	5
2	6â€Shogaol (enexasogoal) treatment improves experimental knee osteoarthritis exerting a pleiotropic effect over immune innate signalling responses in chondrocytes. British Journal of Pharmacology, 2022, 179, 5089-5108.	5.4	8
3	Joint obesity as a pathogenic factor in osteoarthritis. Osteoarthritis and Cartilage, 2021, 29, 1239-1241.	1.3	2
4	Response to: â€˜Correspondence on â€œGlucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?â€™ by Angelides and Manolios. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2020-219721.	0.9	0
5	Criterion validity of ultrasound in the identification of calcium pyrophosphate crystal deposits at the knee: an OMERACT ultrasound study. Annals of the Rheumatic Diseases, 2021, 80, 261-267.	0.9	30
6	Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor. International Journal of Molecular Sciences, 2021, 22, 11490.	4.1	3
7	Ultrasound salivary gland involvement in Sjogrenâ€™s syndrome vs. other connective tissue diseases: is it autoantibody and gland dependent?. Clinical Rheumatology, 2020, 39, 1207-1215.	2.2	20
8	Treating osteoporotic osteoarthritis, or the art of cutting a balding man's hair. Osteoarthritis and Cartilage, 2020, 28, 239-241.	1.3	4
9	Modulation of the Inflammatory Process by Hypercholesterolemia in Osteoarthritis. Frontiers in Medicine, 2020, 7, 566250.	2.6	11
10	Setting up distinctive outcome measures for each osteoarthritis phenotype. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093796.	2.7	13
11	Purinergic System Signaling in Metainflammation-Associated Osteoarthritis. Frontiers in Medicine, 2020, 7, 506.	2.6	13
12	Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?. Annals of the Rheumatic Diseases, 2020, 79, 1261-1263.	0.9	16
13	Disorganization of chondrocyte columns in the growth plate does not aggravate experimental osteoarthritis in mice. Scientific Reports, 2020, 10, 10745.	3.3	14
14	Adenosine Deaminase as a Biomarker of Tenofovir Mediated Inflammation in NaÃ¯ve HIV Patients. International Journal of Molecular Sciences, 2020, 21, 3590.	4.1	4
15	Why we should definitely include intra-articular hyaluronic acid as a therapeutic option in the management of knee osteoarthritis: Results of an extensive critical literature review. Seminars in Arthritis and Rheumatism, 2019, 48, 563-572.	3.4	110
16	2018 update of the EULAR recommendations for the management of hand osteoarthritis. Annals of the Rheumatic Diseases, 2019, 78, 16-24.	0.9	273
17	Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say?. Drugs and Aging, 2019, 36, 15-24.	2.7	146
18	Recommendations for the Reporting of Harms in Manuscripts on Clinical Trials Assessing Osteoarthritis Drugs: A Consensus Statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Drugs and Aging, 2019, 36, 145-159.	2.7	15

#	Article	IF	Citations
19	Chondrocyte enlargement is a marker of osteoarthritis severity. Osteoarthritis and Cartilage, 2019, 27, 1229-1234.	1.3	19
20	An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism, 2019, 49, 337-350.	3.4	392
21	Inhibition of pSTAT1 by tofacitinib accounts for the early improvement of experimental chronic synovitis. Journal of Inflammation, 2019, 16, 2.	3.4	11
22	Recessive mutations in muscle-specific isoforms of FXR1 cause congenital multi-minicore myopathy. Nature Communications, 2019, 10, 797.	12.8	24
23	Targeting chronic innate inflammatory pathways, the main road to prevention of osteoarthritis progression. Biochemical Pharmacology, 2019, 165, 24-32.	4.4	72
24	It Is the Time to Think About a Treat-to-Target Strategy for Knee Osteoarthritis . Therapeutics and Clinical Risk Management, 2019, Volume 15, 1479-1482.	2.0	2
25	Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements. Therapeutic Advances in Musculoskeletal Disease, 2019, 11, 1759720X1989380.	2.7	34
26	Type 2 diabetes mellitus and osteoarthritis. Seminars in Arthritis and Rheumatism, 2019, 49, 9-19.	3.4	110
27	Tenofovir Causes Bone Loss via Decreased Bone Formation and Increased Bone Resorption, Which Can Be Counteracted by Dipyridamole in Mice. Journal of Bone and Mineral Research, 2019, 34, 923-938.	2.8	26
28	Parathyroid hormone-related protein exhibits antioxidant features in osteoblastic cells through its N-terminal and osteostatin domains. Bone and Joint Research, 2018, 7, 58-68.	3.6	23
29	Validation of Musculoskeletal Ultrasound in the Assessment of Experimental Gout Synovitis. Ultrasound in Medicine and Biology, 2018, 44, 1516-1524.	1.5	4
30	Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism, 2018, 48, 1-8.	3.4	25
31	Mediators and Patterns of Muscle Loss in Chronic Systemic Inflammation. Frontiers in Physiology, 2018, 9, 409.	2.8	50
32	Does anti-tumour necrosis factor alpha therapy exert a long-term structural benefit in hand osteoarthritis?. Rheumatology, 2018, 57, 1879-1880.	1.9	0
33	Use of Intraarticular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice. Arthritis Care and Research, 2017, 69, 1287-1296.	3.4	95
34	The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology. Rheumatology International, 2017, 37, 1227-1236.	3.0	22
35	Chondroitin sulfate â€" CONCEPT clear, uncertainties unchanged. Nature Reviews Rheumatology, 2017, 13, 576-577.	8.0	3
36	Unexpected Bone Formation Produced by RANKL Blockade. Trends in Endocrinology and Metabolism, 2017, 28, 695-704.	7.1	20

#	Article	IF	Citations
37	Reply. Arthritis and Rheumatology, 2017, 69, 2093-2094.	5.6	0
38	Compensatory anabolic signaling in the sarcopenia of experimental chronic arthritis. Scientific Reports, 2017, 7, 6311.	3.3	23
39	Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis. British Journal of Pharmacology, 2017, 174, 3018-3031.	5.4	38
40	Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Sixâ€Month Multicenter, Randomized, Doubleâ€Blind, Placeboâ€Controlled Clinical Trial. Arthritis and Rheumatology, 2017, 69, 77-85.	5.6	94
41	Clinical settings in knee osteoarthritis: Pathophysiology guides treatment. Maturitas, 2017, 96, 54-57.	2.4	51
42	The combined therapy with chondroitin sulfate plus glucosamine sulfate or chondroitin sulfate plus glucosamine hydrochloride does not improve joint damage in an experimental model of knee osteoarthritis in rabbits. European Journal of Pharmacology, 2017, 794, 8-14.	3.5	21
43	Increased synovial lipodystrophy induced by high fat diet aggravates synovitis in experimental osteoarthritis. Arthritis Research and Therapy, 2017, 19, 264.	3.5	44
44	The adipokine lipocalin-2 in the context of the osteoarthritic osteochondral junction. Scientific Reports, 2016, 6, 29243.	3.3	25
45	An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease. Expert Opinion on Pharmacotherapy, 2016, 17, 1745-1756.	1.8	39
46	Aromatase expression in human chondrocytes: An induction due to culture. Maturitas, 2016, 85, 27-33.	2.4	6
47	Meniscal degeneration in human knee osteoarthritis: in situ hybridization and immunohistochemistry study. Archives of Orthopaedic and Trauma Surgery, 2016, 136, 175-183.	2.4	21
48	Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. Current Medical Research and Opinion, 2015, 31, 1041-1045.	1.9	22
49	Randomized clinical trials as reflexiveâ€"interpretative process in patients with rheumatoid arthritis: a qualitative study. Rheumatology International, 2015, 35, 1423-1430.	3.0	4
50	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis. Drugs and Aging, 2015, 32, 179-187.	2.7	82
51	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty. Drugs and Aging, 2015, 32, 525-535.	2.7	31
52	DXA in the assessment of subchondral bone mineral density in knee osteoarthritisâ€"A semi-standardized protocol after systematic review. Seminars in Arthritis and Rheumatism, 2015, 45, 275-283.	3.4	11
53	Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement. Osteoarthritis and Cartilage, 2015, 23, 2086-2093.	1.3	47
54	Characterization of multinucleated giant cells in synovium and subchondral bone in knee osteoarthritis and rheumatoid arthritis. BMC Musculoskeletal Disorders, 2015, 16, 226.	1.9	61

#	Article	IF	Citations
55	TLR4 signalling in osteoarthritisâ€"finding targets for candidate DMOADs. Nature Reviews Rheumatology, 2015, 11, 159-170.	8.0	188
56	Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: caseâ€"control study. Arthritis Research and Therapy, 2014, 16, 436.	3.5	5
57	Osteoarthritis: a progressive disease with changing phenotypes. Rheumatology, 2014, 53, 1-3.	1.9	87
58	Targeting subchondral bone in osteoporotic osteoarthritis. Arthritis Research and Therapy, 2014, 16, 494.	3.5	26
59	Description of a new family with cryopyrin-associated periodic syndrome: risk of visual loss in patients bearing the R260W mutation. Rheumatology, 2014, 53, 1095-1099.	1.9	24
60	6â€Shogaol inhibits chondrocytesâ€™ innate immune responses and cathepsinâ€‹scp›K‹/scp› activity. Molecular Nutrition and Food Research, 2014, 58, 256-266.	3.3	37
61	An OA phenotype may obtain major benefit from bone-acting agents. Seminars in Arthritis and Rheumatism, 2014, 43, 421-428.	3.4	31
62	Is lecturing in Rheumatology Satellite Symposia a male attribute?. Rheumatology International, 2014, 34, 287-288.	3.0	7
63	Selective estrogen receptor modulators (SERMs): New alternatives for osteoarthritis?. Maturitas, 2014, 77, 380-384.	2.4	30
64	SDF-1 signaling: a promising target in rheumatic diseases. Expert Opinion on Therapeutic Targets, 2014, 18, 1077-1087.	3.4	50
65	O-linked N-acetylglucosamine (O-GlcNAc) protein modification is increased in the cartilage of patients with knee osteoarthritis. Osteoarthritis and Cartilage, 2014, 22, 259-263.	1.3	28
66	‹scp›PTH‹/scp› [1â€34] enhances bone response around titanium implants in a rabbit model of osteoporosis. Clinical Oral Implants Research, 2013, 24, 1027-1034.	4.5	46
67	Physiological effects of oral glucosamine on joint health: current status and consensus on future research priorities. BMC Research Notes, 2013, 6, 115.	1.4	25
68	Osteoporotic OA: a reasonable target for bone-acting agents. Nature Reviews Rheumatology, 2013, 9, 448-450.	8.0	34
69	Â¿OsteoinmunologÃa, osteo-reumatologÃa o reumatologÃa sin mÃ¡s?. ReumatologÃa ClÃnica, 2013, 9, 257-258.	0.5	0
70	Update on the use of abatacept for the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology, 2013, 9, 599-621.	3.0	13
71	Citrullination enhances the pro-inflammatory response to fibrin in rheumatoid arthritis synovial fibroblasts. Annals of the Rheumatic Diseases, 2013, 72, 1400-1406.	0.9	52
72	Dynamic ultrasound assessment of medial meniscal subluxation in knee osteoarthritis. Rheumatology, 2013, 52, 1443-1447.	1.9	30

#	Article	IF	Citations
73	Lipid Transport and Metabolism in Healthy and Osteoarthritic Cartilage. International Journal of Molecular Sciences, 2013, 14, 20793-20808.	4.1	89
74	Viscosupplementation for Osteoarthritis of the Knee. Annals of Internal Medicine, 2013, 158, 74.	3.9	1
75	Hypercholesterolemia boosts joint destruction in chronic arthritis. An experimental model aggravated by foam macrophage infiltration. Arthritis Research and Therapy, 2013, 15, R81.	3.5	27
76	Estrogen-Dependent Transcriptional Activity: A Protection Against ROS in Osteoarthritis. , 2013, , 369-391.		1
77	Subchondral bone remodelling and osteoarthritis. Arthritis Research and Therapy, 2012, 14, .	3.5	3
78	The Increase in O-Linked N-Acetylglucosamine Protein Modification Stimulates Chondrogenic Differentiation Both in Vitro and in Vivo. Journal of Biological Chemistry, 2012, 287, 33615-33628.	3.4	80
79	Mecanismo de acciÃ³n de abatacept: concordancia con su perfil clÃnico. ReumatologÃa ClÃnica, 2012, 8, 78-83.	0.5	62
80	Abatacept Mechanism of Action: Concordance With Its Clinical Profile. ReumatologÃa ClÃnica (English) Tj ETQq0 0 0 rgBT /Overlock 10	0.3	28
81	Effects of PTH [1-34] on synoviopathy in an experimental model of osteoarthritis preceded by osteoporosis. Osteoarthritis and Cartilage, 2012, 20, 1619-1630.	1.3	22
82	RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis. Arthritis Research and Therapy, 2012, 14, R149.	3.5	49
83	Subchondral bone as a key target for osteoarthritis treatment. Biochemical Pharmacology, 2012, 83, 315-323.	4.4	220
84	Study of the O-linked-N-acetyl-glucosaminylation of proteins induced by high doses of glucosamine and its correlation with osteoarthritis progression. Osteoarthritis and Cartilage, 2012, 20, S126.	1.3	2
85	A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. Annals of the Rheumatic Diseases, 2011, 70, 1957-1962.	0.9	159
86	No Xenotropic Murine Leukemia Virusâ€"related Virus Detected in Fibromyalgia Patients. Emerging Infectious Diseases, 2011, 17, 314-315.	4.3	11
87	Do Clinical Practice Guidelines Do Enough to Help Clinicians Identify Patients at High Risk of Osteoporotic Fracture?. Journal of Clinical Rheumatology, 2011, 17, S57.	0.9	0
88	Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. Osteoarthritis and Cartilage, 2011, 19, 1228-1236.	1.3	98
89	An experimental study of COMP (cartilage oligomeric matrix protein) in the rabbit menisci. Archives of Orthopaedic and Trauma Surgery, 2011, 131, 1167-1176.	2.4	12
90	Bone mineral density and joint cartilage: four clinical settings of a complex relationship in osteoarthritis. Annals of the Rheumatic Diseases, 2011, 70, 1523-1525.	0.9	47

#	Article	IF	Citations
91	Glucosamine sulfate for knee osteoarthritis: science and evidence-based use. Therapy: Open Access in Clinical Medicine, 2010, 7, 591-604.	0.2	4
92	244 OSTEOARTHRITIS LEADS TO INCREASED LEVELS OF PROTEIN O-LINKED N-ACETYLGLUCOSAMINE IN THE CARTILAGE. Osteoarthritis and Cartilage, 2010, 18, S111-S112.	1.3	2
93	Improvement of experimental accelerated atherosclerosis by chondroitin sulphate. Osteoarthritis and Cartilage, 2010, 18, S12-S16.	1.3	8
94	Chondroitin sulfate improves synovitis in rabbits with chronic antigen-induced arthritis. Osteoarthritis and Cartilage, 2010, 18, S17-S23.	1.3	18
95	Efficacy and safety of a selective estrogen receptor Î² agonist, ERBâ€041, in patients with rheumatoid arthritis: A 12â€week, randomized, placeboâ€controlled, phase II study. Arthritis Care and Research, 2010, 62, 1588-1593.	3.4	40
96	Nonsteroidal antiinflammatory drugs and prostaglandin E₂ modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis. Arthritis and Rheumatism, 2010, 62, 478-488.	6.7	42
97	Effects of estrogen deficiency and low bone mineral density on healthy knee cartilage in rabbits. Journal of Orthopaedic Research, 2010, 28, 812-818.	2.3	26
98	Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits. British Journal of Pharmacology, 2010, 161, 1012-1022.	5.4	14
99	Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. International Journal of Clinical Practice, 2010, 64, 756-762.	1.7	32
100	PTH Increases Jaw Mineral Density in a Rabbit Model of Osteoporosis. Journal of Dental Research, 2010, 89, 360-365.	5.2	27
101	EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Annals of the Rheumatic Diseases, 2010, 69, 483-489.	0.9	499
102	Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis. Arthritis Research and Therapy, 2010, 12, R152.	3.5	180
103	Effect of a high dose of glucosamine on systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H268-H276.	3.2	49
104	Correlation between arthroscopic and histopathological grading systems of articular cartilage lesions in knee osteoarthritis. Osteoarthritis and Cartilage, 2009, 17, 205-212.	1.3	31
105	Primary Osteoarthritis No Longer Primary: Three Subsets with Distinct Etiological, Clinical, and Therapeutic Characteristics. Seminars in Arthritis and Rheumatism, 2009, 39, 71-80.	3.4	130
106	Differential effects of the antioxidant n-acetylcysteine on the production of catabolic mediators in IL-1Î²-stimulated human osteoarthritic synoviocytes and chondrocytes. European Journal of Pharmacology, 2009, 623, 125-131.	3.5	32
107	Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors. Arthritis and Rheumatism, 2009, 60, 2558-2564.	6.7	55
108	Lack of Association with Rheumatoid Arthritis of Selected Polymorphisms in 4 Candidate Genes: CFH, CD209, Eotaxin-3, and MHC2TA. Journal of Rheumatology, 2009, 36, 1590-1595.	2.0	15

#	Article	IF	Citations
109	Genetic variation in the nuclear factor ÎºB pathway in relation to susceptibility to rheumatoid arthritis. Annals of the Rheumatic Diseases, 2009, 68, 579-583.	0.9	40
110	Osteoarthritis associated with estrogen deficiency. Arthritis Research and Therapy, 2009, 11, 241.	3.5	236
111	Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-ÎºB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility. Arthritis Research and Therapy, 2009, 11, R42.	3.5	51
112	Characterization of a new experimental model of osteoporosis in rabbits. Journal of Bone and Mineral Metabolism, 2008, 26, 53-59.	2.7	99
113	Does oral glucosamine prevent subchondral bone loss in an animal model of osteoarthritis? Comment on the article by Wang et al. Arthritis and Rheumatism, 2008, 58, 635-635.	6.7	5
114	Chronic arthritis aggravates vascular lesions in rabbits with atherosclerosis: A novel model of atherosclerosis associated with chronic inflammation. Arthritis and Rheumatism, 2008, 58, 2723-2734.	6.7	26
115	Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. British Journal of Pharmacology, 2008, 154, 843-851.	5.4	47
116	Involvement of platelet-activating factor and tumour necrosis factor in the pathogenesis of joint inflammation in rabbits. Clinical and Experimental Immunology, 2008, 88, 318-323.	2.6	19
117	IL-1Î² and IL-6 stimulate the production of platelet-activating factor (PAF) cultured rabbit synovial cells. Clinical and Experimental Immunology, 2008, 99, 364-368.	2.6	14
118	Grado de conocimiento de la osteoporosis en mujeres posmenopÃ¡usicas. Revista EspaÃ±ola De Enfermedades MetabÃ³licas Ã“seas, 2008, 17, 71-75.	0.0	0
119	Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. Osteoarthritis and Cartilage, 2008, 16, 1484-1493.	1.3	43
120	Diacerein has a weak effect on the catabolic pathway of human osteoarthritis synovial fibroblast--comparison to its effects on osteoarthritic chondrocytes. Rheumatology, 2008, 47, 627-633.	1.9	32
121	EULAR evidence based recommendations for the management of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Annals of the Rheumatic Diseases, 2007, 66, 377-388.	0.9	738
122	A Sonographic Enthesitic Index of lower limbs is a valuable tool in the assessment of ankylosing spondylitis. Annals of the Rheumatic Diseases, 2007, 66, 1015-1019.	0.9	140
123	The reverse glucosamine sulfate pathway: application in knee osteoarthritis. Expert Opinion on Pharmacotherapy, 2007, 8, 215-225.	1.8	8
124	Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: A randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis and Rheumatism, 2007, 56, 555-567.	6.7	248
125	Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 3928-3939.	6.7	194
126	Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits. Osteoarthritis and Cartilage, 2007, 15, 69-77.	1.3	102

#	Article	IF	Citations
127	Prostaglandin E2 receptors EP1 and EP4 are up-regulated in rabbit chondrocytes by IL-1Î², but not by TNFÎ±. Rheumatology International, 2007, 27, 911-917.	3.0	16
128	Bone mineral measurements of subchondral and trabecular bone in healthy and osteoporotic rabbits. Skeletal Radiology, 2006, 35, 34-41.	2.0	118
129	Commentary: osteoarthritis of the knee and glucosamine. Osteoarthritis and Cartilage, 2006, 14, 963-966.	1.3	42
130	Ectopic calcification among families in the Azores: Clinical and radiologic manifestations in families with diffuse idiopathic skeletal hyperostosis and chondrocalcinosis. Arthritis and Rheumatism, 2006, 54, 1340-1349.	6.7	44
131	Ultrasonographic assessment of Baker's cysts after intra-articular corticosteroid injection in knee osteoarthritis. Journal of Clinical Ultrasound, 2006, 34, 113-117.	0.8	55
132	Use of crystalline glucosamine sulfate in osteoarthritis. Future Rheumatology, 2006, 1, 397-414.	0.2	3
133	Expression of the peptide C4b-binding protein Â in the arthritic joint. Annals of the Rheumatic Diseases, 2006, 65, 1279-1285.	0.9	8
134	Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Annals of the Rheumatic Diseases, 2006, 65, 998-1005.	0.9	70
135	Cartilage oligomeric matrix protein (COMP) is modified by intra-articular liposomal clodronate in an experimental model of arthritis. Clinical and Experimental Rheumatology, 2006, 24, 622-8.	0.8	9
136	Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoarthritis and Cartilage, 2005, 13, 13-19.	1.3	62
137	EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Annals of the Rheumatic Diseases, 2005, 64, 669-681.	0.9	704
138	A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases, 2005, 64, 64-69.	0.9	90
139	Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: an open-label study to assess pain control. Current Medical Research and Opinion, 2004, 20, 1967-1977.	1.9	19
140	Sequential changes of parathyroid hormone related protein (PTHrP) in articular cartilage during progression of inflammatory and degenerative arthritis. Annals of the Rheumatic Diseases, 2004, 63, 917-922.	0.9	18
141	EP2/EP4 signalling inhibits monocyte chemoattractant protein-1 production induced by interleukin 1Â in synovial fibroblasts. Annals of the Rheumatic Diseases, 2004, 63, 1197-1204.	0.9	40
142	Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis and Cartilage, 2004, 12, 263-268.	1.3	117
143	Histopathological correlation of cartilage swelling detected by magnetic resonance imaging in early experimental osteoarthritis. Osteoarthritis and Cartilage, 2004, 12, 878-886.	1.3	120
144	Transdermal fentanyl for the treatment of pain caused by rheumatoid arthritis. Rheumatology International, 2004, 24, 325-332.	3.0	13

#	Article	IF	Citations
145	Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Annals of the Rheumatic Diseases, 2004, 63, 759-766.	0.9	190
146	Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. Clinical Therapeutics, 2004, 26, 245-256.	2.5	97
147	Glucosamine inhibits IL-1Î²-induced NFÎºB activation in human osteoarthritic chondrocytes. Osteoarthritis and Cartilage, 2003, 11, 290-298.	1.3	341
148	HLA-B27 in patients with a permanent pacemaker. Annals of the Rheumatic Diseases, 2003, 62, 1018-1018.	0.9	2
149	A fibrin based model for rheumatoid synovitis. Annals of the Rheumatic Diseases, 2003, 62, 1135-1138.	0.9	45
150	EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Annals of the Rheumatic Diseases, 2003, 62, 1145-1155.	0.9	1,661
151	Fibrin generated in the synovial fluid activates intimal cells from their apical surface: a sequential morphological study in antigen-induced arthritis. British Journal of Rheumatology, 2003, 42, 19-25.	2.3	28
152	Modulation of cell recruitment by anti-inflammatory agents in antigen-induced arthritis. Annals of the Rheumatic Diseases, 2002, 61, 1027-1030.	0.9	32
153	Studies of Piroxicam Absorption by Oral Mucosa. Arzneimittelforschung, 2002, 52, 385-387.	0.4	4
154	Prevalence of spondyloarthritis in Terceira, Azores: a population based study. Annals of the Rheumatic Diseases, 2002, 61, 551-553.	0.9	23
155	Cartilage and bone biological markers in the synovial fluid of osteoarthritic patients after hyaluronan injections in the knee. Clinica Chimica Acta, 2001, 308, 107-115.	1.1	19
156	High-resolution MRI detects cartilage swelling at the early stages of experimental osteoarthritis. Osteoarthritis and Cartilage, 2001, 9, 463-472.	1.3	141
157	EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Annals of the Rheumatic Diseases, 2000, 59, 936-944.	0.9	458
158	Cyclosporin A prevents the histologic damage of antigen arthritis without inducing fibrosis. Arthritis and Rheumatism, 2000, 43, 311.	6.7	13
159	Pulmonary infiltrates and abdominal colic pain in a patient with a connective tissue disorder. Annals of the Rheumatic Diseases, 2000, 59, 15-19.	0.9	1
160	Biochemical markers of bone remodeling and bone sialoprotein in ankylosing spondylitis. Clinica Chimica Acta, 1999, 289, 99-110.	1.1	18
161	Tenidap decreases IL-8 and monocyte chemotactic peptide-1 (MCP-1) mRNA expression in the synovial tissue of rabbits with antigen arthritis and in cultured synovial cells. Clinical and Experimental Immunology, 1998, 111, 588-596.	2.6	22
162	PAF, a potent proinflammatory mediator, looking for its role in the pathogenesis of joint damage. Annals of the Rheumatic Diseases, 1997, 56, 211-213.	0.9	2

#	Article	IF	Citations
163	SAMe restores the changes in the proliferation and in the synthesis of fibronectin and proteoglycans induced by tumour necrosis factor alpha on cultured rabbit synovial cells. Rheumatology, 1997, 36, 27-31.	1.9	13
164	Antifibroproliferative effect of tenidap in chronic antigen-induced arthritis. Arthritis and Rheumatism, 1997, 40, 2147-2156.	6.7	8
165	Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis. Journal of Lipid Mediators and Cell Signalling, 1996, 13, 35-49.	0.9	18
166	Endothelin-1 induces loss of proteoglycans and enhances fibronectin and collagen production in cultured rabbit synovial cells. European Journal of Pharmacology, 1996, 302, 191-197.	3.5	18
167	Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents and Actions, 1994, 41, 171-178.	0.7	61
168	LIMITED FORMS OF WEGENER'S GRANULOMATOSIS PRESENTING AS POLYMYALGIA RHEUMATICA. Rheumatology, 1991, 30, 382-384.	1.9	7
169	Differences between radiographic abnormalities of acromegalic arthropathy and those of osteoarthritis. Arthritis and Rheumatism, 1990, 33, 455-456.	6.7	10
170	Beneficial effect of fibronectin administration on chronic nephritis in rats. Arthritis and Rheumatism, 1990, 33, 685-692.	6.7	11
171	Selective IgA deficiency and spondyloarthropathy: a distinct disease?. Annals of the Rheumatic Diseases, 1990, 49, 636-637.	0.9	19
172	Elevated Plasma Fibronectin Levels in Rats with Immune and Toxic Glomerular Diseases. Renal Failure, 1990, 12, 227-232.	2.1	6
173	Postsalmonella reactive phenomena in 2 patients with ankylosing spondylitis: no modification of the underlying disease. Journal of Rheumatology, 1990, 17, 250-1.	2.0	5
174	Defective function of the mononuclear phagocytic system in rats with chronic nephritis. Evidence of a decreased degradation of IgG aggregates by Kupffer cells. Immunology, 1988, 63, 87-92.	4.4	5
175	References from the classical rheumatologic literature. Arthritis and Rheumatism, 1985, 28, 1320-1320.	6.7	0
176	Protein-losing enteropathy caused by systemic lupus erythematosus. Gut, 1985, 26, 757-758.	12.1	0
177	Pulmonary Hemorrhage in Lupus Erythematosus Without Evidence of an Immunologic Cause. Archives of Internal Medicine, 1985, 145, 2128.	3.8	5
178	Massive pulmonary hemorrhage: fatal complication of systemic lupus erythematosus. Journal of Rheumatology, 1985, 12, 186-7.	2.0	13
179	Arthritis in beta-thalassemia minor. Arthritis and Rheumatism, 1983, 26, 1292-1293.	6.7	16